Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against West Pharmaceutical Services, Inc. due to allegations of misleading statements and operational inefficiencies that have negatively impacted the company's financial performance [2][4]. Group 1: Allegations Against West Pharmaceutical Services - The complaint alleges that West and its executives violated federal securities laws by making false and misleading statements regarding customer demand and product performance [4]. - Specific claims include that West was experiencing significant destocking in its High-Value Products portfolio, contrary to its public statements [4]. - The SmartDose device, which was marketed as a high-margin growth product, was actually dilutive to profit margins due to operational inefficiencies [4]. - The company faced risks of costly restructuring activities, including exiting contracts with long-standing customers in the continuous glucose monitoring sector [4]. Group 2: Financial Impact and Stock Performance - The truth about the company's financial struggles was revealed on February 13, 2025, when West issued weak revenue and earnings forecasts for 2025, attributing this to contract manufacturing challenges and the loss of major customers [5]. - Following this announcement, West's stock price plummeted by $123.17 per share, a decline of 38%, closing at $199.11 [5]. Group 3: Legal Proceedings and Investor Actions - Investors who purchased securities in West between February 16, 2023, and February 12, 2025, are encouraged to discuss their legal rights and options with Faruqi & Faruqi [1][2]. - There is a deadline of July 7, 2025, for investors to seek the role of lead plaintiff in the federal securities class action against West [2][6]. - The firm is also seeking information from whistleblowers, former employees, and shareholders regarding West's conduct [7].

NEW YORK, June 20, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in West Pharmaceutical Services, Inc. ("West Pharmaceutical Services, Inc." or the "Company") (NYSE: WST) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of West Pharmaceutical Services, Inc. investors who were adversely affected by alleged securities fraud between February 16, 2023 and February 12, 2025. Follow the link below to get more information and be contacted by a mem ...

Core Viewpoint - A class action securities lawsuit has been filed against West Pharmaceutical Services, Inc. alleging securities fraud that negatively impacted investors between February 16, 2023, and February 12, 2025 [1][2]. Group 1: Lawsuit Details - The lawsuit claims that West Pharmaceutical Services made false statements regarding customer demand and attributed challenges to temporary COVID-related product destocking, while in reality, the company faced significant ongoing destocking in its high-margin HVP portfolio [3]. - It is alleged that West's SmartDose device, which was marketed as a high-margin growth product, actually diluted the company's profit margins due to operational inefficiencies [3]. - The margin pressures from these issues raised the risk of costly restructuring activities, including the company's exit from continuous glucose monitoring contracts with long-standing customers [3]. - As a result of these factors, the positive statements made by the defendants about the company's business and prospects were materially false or misleading [3]. Group 2: Next Steps for Investors - Investors who suffered losses during the specified timeframe have until July 7, 2025, to request to be appointed as lead plaintiff in the case [4]. - Participation in the lawsuit does not require serving as a lead plaintiff, and class members may be entitled to compensation without any out-of-pocket costs or fees [4]. Group 3: Law Firm Background - Levi & Korsinsky, LLP has a history of securing hundreds of millions of dollars for shareholders and has been recognized as one of the top securities litigation firms in the United States for seven consecutive years [5].

Core Viewpoint - A class action securities lawsuit has been filed against West Pharmaceutical Services, Inc. for alleged securities fraud affecting investors between February 16, 2023, and February 12, 2025 [1][2]. Group 1: Lawsuit Details - The lawsuit aims to recover losses for investors who were negatively impacted by alleged fraudulent activities during the specified period [2]. - The complaint alleges that West Pharmaceutical Services made false statements regarding customer demand and concealed ongoing destocking issues in its high-margin HVP portfolio [3]. - It is claimed that the SmartDose device, which was marketed as a high-margin growth product, actually diluted profit margins due to operational inefficiencies [3]. - The lawsuit also highlights that margin pressures could lead to costly restructuring activities, including the exit from continuous glucose monitoring contracts with long-term customers [3]. - As a result of these issues, the positive statements made by the defendants about the company's business and prospects were deemed materially false or misleading [3]. Group 2: Next Steps for Investors - Investors who suffered losses during the relevant timeframe have until July 7, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require serving as a lead plaintiff [4]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [4]. Group 3: Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and has a strong track record in complex securities litigation [5]. - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as one of the leading securities litigation firms in the United States [5].

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of West Pharmaceutical Services, Inc. regarding a class action lawsuit alleging that the company made materially false and misleading statements during the class period from February 16, 2023, to February 12, 2025 [1] Allegations - The complaint alleges that West Pharmaceutical Services claimed strong visibility into customer demand while actually experiencing significant destocking in its high-margin HVP portfolio [1] - The SmartDose device, positioned as a high-margin growth product, was found to be dilutive to profit margins due to operational inefficiencies [1] - Margin pressures from these issues raised the risk of costly restructuring activities, including exiting continuous glucose monitoring contracts with longstanding customers [1] - Positive statements made by the defendants regarding the company's business and prospects were deemed materially false or misleading [1] Class Action Details - Shareholders who purchased shares of WST during the specified class period are encouraged to register for the class action, with a deadline of July 7, 2025, to seek lead plaintiff status [2] - Registered shareholders will receive updates through a portfolio monitoring software throughout the lifecycle of the case [2] Law Firm's Mission - The Gross Law Firm aims to protect the rights of investors who have suffered due to deceit, fraud, and illegal business practices, ensuring companies adhere to responsible business practices [3]

Core Viewpoint - Rosen Law Firm is reminding investors who purchased common stock of West Pharmaceutical Services, Inc. during the specified Class Period of the upcoming lead plaintiff deadline on July 7, 2025 [1] Group 1: Class Action Details - Investors who purchased West Pharmaceutical common stock between February 16, 2023, and February 12, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2] - A class action lawsuit has already been filed, and interested parties can join by contacting Rosen Law Firm [3][6] - To serve as lead plaintiff, individuals must file a motion with the Court by July 7, 2025 [3] Group 2: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company at the time [4] - The firm was ranked No. 1 by ISS Securities Class Action Services for the number of securities class action settlements in 2017 and has consistently ranked in the top 4 since 2013 [4] - In 2019, the firm secured over $438 million for investors, showcasing its capability in recovering significant amounts for clients [4] Group 3: Case Allegations - The lawsuit alleges that West Pharmaceutical made false and misleading statements regarding its business operations, particularly concerning its High-Value Products portfolio and the SmartDose device [5] - It is claimed that West was experiencing significant destocking in its high-margin products, contrary to its public statements [5] - The lawsuit also highlights operational inefficiencies that negatively impacted profit margins and led to potential restructuring activities [5]

Core Viewpoint - Rosen Law Firm is reminding investors who purchased common stock of West Pharmaceutical Services, Inc. during the specified Class Period of the upcoming lead plaintiff deadline on July 7, 2025 [1] Group 1: Class Action Details - Investors who bought West common stock between February 16, 2023, and February 12, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2] - A class action lawsuit has already been filed, and interested parties can join by submitting a form or contacting the law firm [3][6] - The lead plaintiff must file a motion with the Court by July 7, 2025, to represent other class members in the litigation [3] Group 2: Law Firm Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [4] - The firm has achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time, and has consistently ranked highly in securities class action settlements since 2013 [4] - In 2019, the firm secured over $438 million for investors, showcasing its capability in recovering funds for clients [4] Group 3: Case Allegations - The lawsuit alleges that West Pharmaceutical Services made false and misleading statements regarding its business operations, particularly concerning its High-Value Products portfolio and the SmartDose device [5] - It is claimed that West was experiencing significant destocking in its high-margin products, contrary to its public statements about strong customer demand [5] - The lawsuit also points to operational inefficiencies in the SmartDose device that negatively impacted profit margins and led to potential restructuring activities [5]

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against West Pharmaceutical Services, Inc. due to allegations of false and misleading statements regarding the company's financial health and operational challenges, particularly related to its High-Value Products portfolio and SmartDose device [2][4]. Group 1: Allegations Against West Pharmaceutical Services - The complaint alleges that West and its executives violated federal securities laws by making false statements and failing to disclose significant destocking issues in their High-Value Products portfolio [4]. - It is claimed that the SmartDose device, which was marketed as a high-margin growth product, actually diluted profit margins due to operational inefficiencies [4]. - The allegations also include that these margin pressures could lead to costly restructuring activities, including the exit from continuous glucose monitoring contracts with long-standing customers [4]. Group 2: Impact of Disclosures - The truth about the alleged fraud was revealed through a series of disclosures, culminating on February 13, 2025, when West issued weak revenue and earnings forecasts for 2025 [5]. - West attributed the disappointing guidance to contract manufacturing challenges, including the loss of two major customers transitioning to in-house manufacturing [5]. - Following this news, West's stock price dropped by $123.17 per share, a decline of 38%, closing at $199.11 on February 13, 2025 [5]. Group 3: Legal Proceedings and Investor Actions - Investors who suffered losses exceeding $100,000 between February 16, 2023, and February 12, 2025, are encouraged to contact Faruqi & Faruqi to discuss their legal options [1]. - There is a deadline of July 7, 2025, for investors to seek the role of lead plaintiff in the federal securities class action against West [2][6]. - The lead plaintiff is defined as the investor with the largest financial interest in the relief sought, who will oversee the litigation on behalf of the class [6].

NEW YORK, June 13, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in West Pharmaceutical Services, Inc. ("West Pharmaceutical Services, Inc." or the "Company") (NYSE: WST) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of West Pharmaceutical Services, Inc. investors who were adversely affected by alleged securities fraud between February 16, 2023 and February 12, 2025. Follow the link below to get more information and be contacted by ...

Core Viewpoint - A class action securities lawsuit has been filed against West Pharmaceutical Services, Inc. alleging securities fraud that affected investors between February 16, 2023, and February 12, 2025 [1][2]. Group 1: Lawsuit Details - The lawsuit claims that West Pharmaceutical Services made false statements regarding its customer demand visibility and attributed headwinds to temporary COVID-related product destocking, while in reality, it was facing significant ongoing destocking in its high-margin HVP portfolio [3]. - It is alleged that West's SmartDose device, which was marketed as a high-margin growth product, actually diluted the company's profit margins due to operational inefficiencies [3]. - The margin pressures from these issues raised the risk of costly restructuring activities, including the company's exit from continuous glucose monitoring contracts with long-standing customers [3]. - As a result of these factors, the positive statements made by the defendants about the company's business, operations, and prospects were materially false and/or misleading [3]. Group 2: Next Steps for Investors - Investors who suffered losses in West Pharmaceutical Services during the specified timeframe have until July 7, 2025, to request to be appointed as lead plaintiff in the case [4]. - Participation in the lawsuit does not require serving as a lead plaintiff, and class members may be entitled to compensation without any out-of-pocket costs or fees [4]. Group 3: Firm Background - Levi & Korsinsky, LLP has a history of securing hundreds of millions of dollars for aggrieved shareholders and has extensive expertise in complex securities litigation [5]. - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as one of the top securities litigation firms in the United States [5].